Structural basis for STAT2 suppression by flavivirus NS5

Boxiao Wang1,11, Stephanie Thurmond2,3,11, Kang Zhou4,11, Maria T. Sánchez-Aparicio5,6,11, Jian Fang1, Jiwei Lu1, Linfeng Gao1,7, Wendan Ren1, Yanxiang Cui4, Ethan C. Veit4, HeaJin Hong1, Matthew J. Evans6, Seán E. O’Leary1, Adolfo García-Sastre5,6,8,9, Z. Hong Zhou1,4,10, Rong Hai1,2,3 and Jikui Song1,7

Suppressing cellular signal transducers of transcription 2 (STAT2) is a common strategy that viruses use to establish infections, yet the detailed mechanism remains elusive, owing to a lack of structural information about the viral–cellular complex involved. Here, we report the cryo-EM and crystal structures of human STAT2 (hSTAT2) in complex with the non-structural protein 5 (NS5) of Zika virus (ZIKV) and dengue virus (DENV), revealing two-pronged interactions between NS5 and hSTAT2. First, the NS5 methyltransferase and RNA-dependent RNA polymerase (RdRP) domains form a conserved interdomain cleft harboring the coiled-coil domain of hSTAT2, thus preventing association of hSTAT2 with interferon regulatory factor 9. Second, the NS5 RdRP domain also binds the amino-terminal domain of hSTAT2. Disruption of these ZIKV NS5–hSTAT2 interactions compromised NS5-mediated hSTAT2 degradation and interferon suppression, and viral infection under interferon-competent conditions. Taken together, these results clarify the mechanism underlying the functional antagonism of STAT2 by both ZIKV and DENV.

The type I interferon (IFN)-mediated innate immune response constitutes the first line of host defense against viral infection1. Induction of type I IFN signaling requires activation of STAT2, which triggers the expression of hundreds of IFN-stimulated genes (ISGs)2 to inhibit infection. To achieve successful infection, viruses must suppress activation of STAT2-triggered IFN responses3. Mechanistic understanding of this ‘arms race’ between hosts and viruses is essential for the development of new therapeutic strategies against viral infections.

STAT2 belongs to the seven-member STAT family of transcriptional regulators4, containing an N-terminal domain (ND), a coiled-coil domain (CCD), a DNA-binding domain (DBD), a linker domain (LD), a SRC homology 2 (SH2) domain, a tyrosine-phosphorylation (pY)-site-containing tail segment and a transcriptional activation domain (TAD) (Fig. 1a). STAT2-mediated transcriptional activation involves tyrosine phosphorylation (pY)-site-containing tail segment and a linker domain (LD), a SRC homology 2 (SH2) domain, a tyrosine-phosphorylation (pY)-site-containing tail segment and a transcriptional activation domain (TAD) (Fig. 1a). STAT2-mediated transcriptional activation involves tyrosine phosphorylation of STAT2 by the Janus kinases (JAKs), followed by formation of a STAT1–STAT2 dimer via a mutual SH2-pY interaction5. In addition, the interaction between STAT2 and IFN regulatory factor 9 (IRF9) further mediates the formation of the IFN-stimulated gene factor-3 (ISGF3) complex6–8, which translocates to the nucleus to activate transcription11. STAT2-suppression schemes3. Prominent examples include DENV and ZIKV, members of the Flavivirus genus of the Flaviviridae family. Both ZIKV and DENV pose serious threats to global public health—ZIKV infection during recent epidemics has been linked to neurological disorders such as congenital microcephaly10 and Guillain–Barré syndrome11, and DENV infection is associated with dengue hemorrhagic fever12. But neither antiviral therapeutics nor vaccines against ZIKV and DENV infections are currently available. Both viruses employ their respective NS5 to suppress hSTAT2-mediated IFN response13–15. NS5 contains an N-terminal methyltransferase (MTase) domain that catalyzes viral RNA capping, and an RdRP domain that is responsible for replicating the viral genome16. These NS5 proteins directly bind to hSTAT2 and promote its degradation through the proteasome-mediated pathway17,18. However, owing to lack of structural information about the NS5–hSTAT2 complexes, the mechanism underlying this NS5-mediated hSTAT2 degradation and IFN suppression remains elusive, limiting our ability to target NS5–hSTAT2 interactions for antiviral intervention.

In this study, we have determined the crystal and cryo electron microscopy (cryo-EM) structures of ZIKV NS5 in complex with hSTAT2, revealing multivalent interactions between ZIKV NS5 and hSTAT2. Structure-guided functional analyses revealed that these interactions compete against the hSTAT2–IRF9 association, and are essential for degradation of hSTAT2, suppression of type I IFN responses, and efficient viral infection. Furthermore, our EM study of the DENV NS5–hSTAT2 complex, together with cellular assays, demonstrates that DENV NS5 interacts with hSTAT2 in a similar fashion as ZIKV NS5 does, suggesting that there is a conserved hSTAT2–NS5-engaging mechanism in the two flaviviruses. Together, these studies provide key insights into the interactions
between viral antagonists and STATs, and a framework for rational designs of vaccines and antivirals.

**Results**

**Crystal structure of the ZIKV RdRP–hSTAT2 complex.** To define the atomic details of the ZIKV NS5–hSTAT2 interaction, we co-crystallized the ZIKV RdRP domain with a fragment of hSTAT2 (residues 1–713; hSTAT21–713) and solved the structure at 3.0-Å resolution (Fig. 1b,c, Table 1 and Supplementary Video 1). We were able to trace NS5 RdRP, the core fragment (CF, residues 137–680) and the pY-tail segment (residues 690–705) of hSTAT2, along with partial hSTAT2 ND (residues 24–68 and residues 76–112) (Fig. 1b,c). The CF of hSTAT2 assumes an elongated fold, similar to that of STAT1 (refs. 17,18) and other STAT proteins19–21, with the CCD, DBD, LD and SH2 domains sequentially packed against each other to form an integrated core. Structural alignment of the hSTAT2 CF with the corresponding region of hSTAT1 gives a root-mean-square deviation (RMSD) of 0.57 Å over 404 Cα atoms, in line with the ~40% sequence identity between the CFs of these two proteins (Supplementary Fig. 1). The RdRP domain adopts a right-hand cup fold composed of palm, fingers and thumb subdomains with two zinc finger clusters, as has been previously observed (Fig. 1b and Extended Data Fig. 1a)22–25. Association of hSTAT2 with NS5 RdRP is mediated by the CCD of hSTAT2, which fills in a surface groove next to the RNA-entrance tunnel of ZIKV RdRP (Extended Data Fig. 1b,c). In addition, the ND of hSTAT2 joins the rest of hSTAT2 only through an unresolved flexible linker and docks at the outer wall of the RNA-exit tunnel of ZIKV RdRP (Extended Data Fig. 1b,d), yielding an average B factor (~123 Å²) that is much higher than that of the rest of the complex (~67 Å²).

---

**Fig. 1 | Crystal structure of the RdRP domain of ZIKV NS5 in complex with hSTAT21–713.** a, ZIKV NS5 and hSTAT2 primary sequences, with domains used for crystallization marked with arrowheads. NLS, nuclear localization signal. b, Ribbon representation of the ZIKV RdRP–hSTAT21–713 complex. The disordered linkers are shown as dashed lines. c, Surface representation of the ZIKV RdRP–hSTAT21–713 complex. The color scheme in a–c is applied to subsequent figures unless otherwise indicated.
The pY-tail segment of hSTAT2 forms a β-strand that augments in antiparallel the β-sheet of the SH2 domain, with the side chain of its R694 forming a salt bridge with a sulfate ion embedded in the pY-engaging pocket of SH2. The same sulfate ion also engages a salt bridge with the potential pY-binding residue R601, mimicking the interaction between SH2 and the phosphate group of pY (Extended Data Fig. 2a,b). Therefore, this intramolecular association of hSTAT2 potentially occludes the hSTAT2 SH2 domain from accessing other pY-containing fragments. At the N terminus of the tail segment, the phosphorylation target Y690 is free of phosphorylation and in contact with SH2 residues H647 and Q649 through side-chain hydrogen-bonding interactions (Extended Data Fig. 2a). These observations provide a rationale for why dimerization of hSTAT2 entails the phosphorylation of STAT2 Y690 (ref. 27), which presumably facilitates the displacement of the hSTAT2 pY-tail segment from the SH2 domain in cis.

It has been demonstrated that the pY-tail segment mediates homodimerization of STAT1, STAT3 and STAT6 proteins through both the reciprocal SH2-pY interaction and antiparallel tail-pairing (Extended Data Fig. 2a,b). Given that the pY-tail segment of hSTAT2 bears high sequence homology with the corresponding fragments of STAT1 and other STAT family members (Extended Data Fig. 2c), it is conceivable that STAT2 heterodimerizes with STAT1 in a similar fashion to homodimerization of STAT1. Along that line, we built a model of the ZIKV NS5–hSTAT2–hSTAT1–DNA complex based on the structure of the hSTAT1 homodimer and the ZIKV NS5–hSTAT2 complexes (Extended Data Fig. 2d). The structural model of the ZIKV NS5–hSTAT2–hSTAT1–DNA complex suggests that hSTAT2 interacts with NS5 and DNA via distinct regions (Extended Data Fig. 2d). The hSTAT2 DBD, like the corresponding region of hSTAT1, participates in DNA binding, through a positively charged surface (Extended Data Fig. 2d).

**Cryo-EM structure of full-length ZIKV NS5–hSTAT2 complex.** To investigate how full-length ZIKV NS5 interacts with hSTAT2, we also determined the structure of full-length NS5 in complex with hSTAT2 (Extended Data Fig. 2, Table 2, Extended Data Figs. 3 and 4, Supplementary Video 2 and Supplementary Fig. 2). Due to structural flexibility and the existence of multiple conformations, the cryo-EM structure has resolutions varying from 3.5–4.0 Å for CCD, MTase and RdRP to 4.0–5.0 Å for DBD to 5.0–7.5 Å for LD and SH2 (Extended Data Fig. 3c). The cryo-EM map is of sufficient quality to allow atomic modeling of CCD, DBD and partial LD of hSTAT2, and both the MTase and RdRP domains of NS5 (Fig. 2a,b and Extended Data Fig. 4). Except for the MTase domain, these individual domains have been modeled in our crystal structure of NS5–hSTAT2 (Extended Data Fig. 3c), which matches well with the cryo-EM density map (Extended Data Fig. 4). This fitting also reveals the densities corresponding to the MTase domain (Extended Data Fig. 4). The atomic model of NS5–hSTAT2 (Extended Data Fig. 3c) shows that the tip of hSTAT2 CCD is anchored at the interdomain cleft formed between the MTase and RdRP domains of NS5 (Fig. 2a,b). This observation, consistent with our domain-mapping analyses ex vivo and in vitro (Extended Data Fig. 5), suggest that both the MTase and RdRP domains of NS5 interact with hSTAT2. Structural comparison of hSTAT2-bound NS5 with the previously reportedly free state (Extended Data Fig. 5) reveals a similar domain orientation between the MTase and RdRP domains (Extended Data Fig. 6a,b), with an RMSD of 2.3 Å over 778 aligned Ca atoms. The major difference between the two states concerns a slight movement of the MTase domain toward the hSTAT2 CCD in the hSTAT2-bound state (Extended Data Fig. 6b). The lack of major changes in the NS5 structure between the two states implies that ZIKV NS5 has evolved with a conformation well poised for interaction with hSTAT2.

The ZIKV RdRP–hSTAT2 association is mediated by complementarity between the convex surfaces formed by the helical ND and CCD of hSTAT2 and two separate surface grooves of RdRP (Fig. 3a–c). Of particular note are the aromatic ring stacking between hSTAT2 F175 and RdRP H855, and the hydrogen bonds between R176 from hSTAT2 CCD and RdRP residues, including the one with the backbone of G850 and the bidentate one with the side chain of D734 (Fig. 3b and Extended Data Fig. 1c). These interactions are reinforced by van der Waals contacts involving Q165, D168, Q169, D171, V172, I179, E195 and T202 of hSTAT2 CCD and V335–T337, L847, W848 and L852 of RdRP (Fig. 3b). At the second interface, hSTAT2 ND approaches the RdRP through van der Waals and hydrogen-bonding interactions involving D53, F61, R92, Q95, S98 and Q99 of hSTAT2 ND and T314, S317, V322, R327, A343 and I750 of RdRP (Fig. 3c and Extended Data Fig. 1d).

The NS5 MTase domain is anchored to the middle segment of hSTAT2 CCD, with the potential RNA-binding surface of the MTase domain arching over the second and fourth helix of hSTAT2 CCD (Fig. 3d–f and Extended Data Fig. 6c,d). Indeed, electrophoretic mobility shift assay (EMSA) confirms that hSTAT2 competes against a capped RNA molecule for ZIKV NS5 binding in vitro (Extended Data Fig. 6e). Notably, an α-helix from the MTase domain, composed of residues S20–Y25, is positioned in close proximity to residues K218, T225, L299, R300, Q303, E306 and R310 of hSTAT2 (Fig. 3d–f), while the loop segment projected from the central β sheet of MTase, containing residues G850 and H855, is docked onto the surface of G850 and the bidentate one with the side chain of D734 (Fig. 3b and Extended Data Fig. 1c). These interactions are reinforced by van der Waals contacts involving Q165, D168, Q169, D171, V172, I179, E195 and T202 of hSTAT2 CCD and V335–T337, L847, W848 and L852 of RdRP (Fig. 3b). At the second interface, hSTAT2 ND approaches the RdRP through van der Waals and hydrogen-bonding interactions involving D53, F61, R92, Q95, S98 and Q99 of hSTAT2 ND and T314, S317, V322, R327, A343 and I750 of RdRP (Fig. 3c and Extended Data Fig. 1d).

The ZIKV RdRP–hSTAT2 association is mediated by complementarity between the convex surfaces formed by the helical ND and CCD of hSTAT2 and two separate surface grooves of RdRP (Fig. 3a–c). Of particular note are the aromatic ring stacking between hSTAT2 F175 and RdRP H855, and the hydrogen bonds between R176 from hSTAT2 CCD and RdRP residues, including the one with the backbone of G850 and the bidentate one with the side chain of D734 (Fig. 3b and Extended Data Fig. 1c). These interactions are reinforced by van der Waals contacts involving Q165, D168, Q169, D171, V172, I179, E195 and T202 of hSTAT2 CCD and V335–T337, L847, W848 and L852 of RdRP (Fig. 3b). At the second interface, hSTAT2 ND approaches the RdRP through van der Waals and hydrogen-bonding interactions involving D53, F61, R92, Q95, S98 and Q99 of hSTAT2 ND and T314, S317, V322, R327, A343 and I750 of RdRP (Fig. 3c and Extended Data Fig. 1d).

The ZIKV RdRP–hSTAT2 association is mediated by complementarity between the convex surfaces formed by the helical ND and CCD of hSTAT2 and two separate surface grooves of RdRP (Fig. 3a–c). Of particular note are the aromatic ring stacking between hSTAT2 F175 and RdRP H855, and the hydrogen bonds between R176 from hSTAT2 CCD and RdRP residues, including the one with the backbone of G850 and the bidentate one with the side chain of D734 (Fig. 3b and Extended Data Fig. 1c). These interactions are reinforced by van der Waals contacts involving Q165, D168, Q169, D171, V172, I179, E195 and T202 of hSTAT2 CCD and V335–T337, L847, W848 and L852 of RdRP (Fig. 3b). At the second interface, hSTAT2 ND approaches the RdRP through van der Waals and hydrogen-bonding interactions involving D53, F61, R92, Q95, S98 and Q99 of hSTAT2 ND and T314, S317, V322, R327, A343 and I750 of RdRP (Fig. 3c and Extended Data Fig. 1d).

The ZIKV RdRP–hSTAT2 association is mediated by complementarity between the convex surfaces formed by the helical ND and CCD of hSTAT2 and two separate surface grooves of RdRP (Fig. 3a–c). Of particular note are the aromatic ring stacking between hSTAT2 F175 and RdRP H855, and the hydrogen bonds between R176 from hSTAT2 CCD and RdRP residues, including the one with the backbone of G850 and the bidentate one with the side chain of D734 (Fig. 3b and Extended Data Fig. 1c). These interactions are reinforced by van der Waals contacts involving Q165, D168, Q169, D171, V172, I179, E195 and T202 of hSTAT2 CCD and V335–T337, L847, W848 and L852 of RdRP (Fig. 3b). At the second interface, hSTAT2 ND approaches the RdRP through van der Waals and hydrogen-bonding interactions involving D53, F61, R92, Q95, S98 and Q99 of hSTAT2 ND and T314, S317, V322, R327, A343 and I750 of RdRP (Fig. 3c and Extended Data Fig. 1d).
**ZIKV NS5-hSTAT2 interaction and cellular localization of ZIKV NS5.** To test our structural observations, we mutated key interaction-defining residues, including Y25 from NS5 MTase; R327, D734 and H855 from NS5 RdRP; and F175 and R176 from hSTAT2. The effects of these mutations on the protein-protein interaction were analyzed by coimmunoprecipitation (co-IP) assays using 293T cells transfected with hemaglutinin (HA)-tagged ZIKV NS5 and FLAG-tagged hSTAT2. The F175A and R176A mutations in hSTAT2 substantially reduced the binding of hSTAT2 with NS5 (Fig. 3g). Likewise, introduction of the D734A H855A (MutDH), Y25A D734A H855A (MutYDH), R327A D734A H855A (MutRDH) or Y25A R327A D734A H855A (MutYRDH) mutations on ZIKV NS5 also largely disturbed the NS5-hSTAT2 interaction (Fig. 3h). Consistently, co-IP assays with endogenous hSTAT2 indicate that hSTAT2 binds strongly to wild-type ZIKV NS5, but not to the MutYRDH mutant (Extended Data Fig. 7a). Additional in vitro GST pull-down assays with these NS5 mutants confirmed the co-IP results (Extended Data Fig. 7b). These data therefore lend strong support to the interaction mechanism identified in our NS5–hSTAT2 complex.

A previous study demonstrated that, as with other flaviviruses, ZIKV NS5 localizes predominantly within the nucleus in the absence of STAT2 overexpression, yet co-expression of ZIKV NS5 with hSTAT2 leads to their colocalization to the cytoplasm. To evaluate the effect of the ZIKV NS5-hSTAT2 interaction on cellular localization of ZIKV NS5, we performed immunofluorescence (IF) assays on ZIKV NS5 and hSTAT2 using 293T cells. Consistent with results of a previous study, co-expression of wild-type ZIKV NS5 with hSTAT2 led to complete retention of ZIKV NS5 in the cytoplasm (Fig. 3i and Extended Data Fig. 7c). By contrast, ~60–90% of NS5 MutDH, MutYDH, MutRDH and MutYRDH mutants were localized inside the nucleus, with hSTAT2 remaining in the cytoplasm (Fig. 3i and Extended Data Fig. 7c). Cytoplasmic colocalization of ZIKV NS5 and hSTAT2 was most severely disrupted with the introduction of the NS5 MutRDH or MutYRDH (Fig. 3i and Extended Data Fig. 7c). These results suggest that the ZIKV NS5-hSTAT2 interaction underlies the cytoplasmic colocalization of ZIKV NS5 and hSTAT2.

**ZIKV NS5 competes against IRF9 for hSTAT2 binding.** STAT2 and IRF9 form a cognate complex in cells, which plays a critical role in regulating the nuclear shuffling of the STAT2 and IFN response. Previous studies revealed that the interaction between STAT2 and IRF9 is also mediated by the STAT2 CCD. Structural comparison of ZIKV NS5- and IRF9-bound STAT2 proteins reveals a remarkably similar surface for ZIKV NS5 and IRF9 binding (Extended Data Fig. 8a,b), and our ITC binding assays also confirmed that both ZIKV NS5 and IRF9 bind to hSTAT2 strongly, with $K_{d}$ falling into the ranges of $\mu$M and sub-$\mu$M, respectively (Extended Data Fig. 8c,d). To determine whether the presence of ZIKV NS5 affects the association of STAT2 with IRF9, we carried out co-IP assays using 293T cells transfected with FLAG-tagged hSTAT2, HA-tagged ZIKV NS5 or Myc-tagged IRF9, and found that increasing expression of NS5 led to a gradual decrease of IRF9-hSTAT2 association, and vice versa (Extended Data Fig. 8e). In accordance with this, an in vitro GST pull-down assay indicated that the association of ZIKV NS5 with hSTAT2 decreases with the increasing amount of IRF9 (Extended Data Fig. 8f). Furthermore, our FLAG-IP assay indicated that the hSTAT2 F175A and R176A mutations, which impair the interaction with ZIKV NS5, also disrupted the hSTAT2-IRF9 interaction (Extended Data Fig. 8g). These data therefore suggest that ZIKV NS5 competes against IRF9 for STAT2 binding, which may consequently disrupt the formation of the ISG3 complex required for antiviral gene expression. Inhibition of ISGF3-complex formation might further contribute to the cytoplasmic retention of hSTAT2, and facilitate NS5-mediated IFN suppression. Together, our structural and functional studies define the atomic details of the NS5–hSTAT2 interaction underlying not only the infection-triggered hSTAT2 degradation, but also possible degradation-independent ISGF3 suppression, leading to multimodal inhibition of IFN responses, and to establishment of successful viral infection.

**DENV-2 and ZIKV NS5s share a similar hSTAT2-binding mechanism.** Sequence analysis of the ZIKV-NS5-interaction sites of NS5 showed relatively high conservation of the CCD region, but less conservation of the ND (Extended Data Fig. 9a,b), which might contribute to the evolutionarily divergent interaction of STAT2 with ZIKV NS5 (ref. 14). On the other hand, the hSTAT2-interacting residues of ZIKV NS5 are considerably conserved in DENV and other flaviviruses. Therefore, the structure of the full-length ZIKV NS5–hSTAT2 complex and the analysis of the effect of the ZIKV NS5-hSTAT2 interaction on cellular localization contribute to the understanding of the evolutionarily divergent and convergent mechanisms of flaviviruses.
members of the flavivirus family (Extended Data Fig. 9c,d), raising the possibility that DENV NS5 might interact with hSTAT2 similarly. To test this, we determined the EM structure of the DENV serotype 2 (DENV-2) NS5–hSTAT2 complex (Fig. 4a and Extended Data Fig. 9e,f). Indeed, DENV-2 NS5 associates with hSTAT2 in a similar manner as ZIKV NS5, with one end of the hSTAT2 CCD mimic of hSTAT2-bound DENV-2 NS5, fits well with the extended conformation of DENV-2 NS5 (Fig. 4a,b), but not with the compact conformation of DENV-3 NS5 (Extended Data Fig. 9g). These observations suggest that there is a conserved conformational selection mechanism in the interaction between flavivirus NS5 and hSTAT2.

Furthermore, we mutated the DENV-2 NS5 residues D732 and L853 to alanine, equivalent to D734 and H855 of ZIKV NS5 (Fig. 4c), and performed co-IP assay using 293T cells cotransfected with FLAG-tagged hSTAT2 and HA-tagged DENV-2 NS5. Wild-type DENV-2 NS5 interacted strongly with hSTAT2, but variants carrying the single mutations D732A or L853A or the double mutation D732A L853A did not (Fig. 4c). In addition, ectopic expression of hSTAT2 led to retention of wild-type, but not D732A L853A-mutated, DENV-2 NS5 in the cytoplasm (Fig. 4d). Together, these data suggest that DENV-2 NS5 and ZIKV NS5 engage hSTAT2 in a similar fashion.

ZIKV NS5–hSTAT2 interaction leads to hSTAT2 degradation and IFN suppression. We further evaluated the effect of the ZIKV NS5–hSTAT2 interaction on the stability of hSTAT2 and the related type I IFN response in cells. Expression of wild-type ZIKV NS5 in 293T cells led to a dose-dependent decrease in the protein level of endogenous hSTAT2 (Fig. 5a), consistent with previous observations. The NS5-dependent degradation of hSTAT2 was slightly attenuated in cells transfected with NS5 Mut<sup>YRDH1</sup>, and became even less evident in cells transfected with NS5 Mut<sup>YRDH2</sup> or Mut<sup>YRDH3</sup> (Fig. 5a). Next, we performed the vesicular stomatitis virus (VSV)–green fluorescent protein (GFP) based IFN bioassay to evaluate the impact of the NS5–hSTAT2 interaction on IFN production. The replication efficiency of VSV, which is impaired in the presence of high levels of IFN, was increased in A549 cells treated with supernatants from cell cultures transfected with wild-type NS5 compared with that in those treated with NS5 Mut<sup>YRDH1</sup> (Fig. 5b), suggesting that the NS5 Mut<sup>YRDH1</sup> mutation impaired NS5-mediated suppression of IFN production. Consistent with these results, quantitative PCR with reverse transcription (RT–qPCR) analysis of two representative type I IFN-stimulated genes, IFN induced protein 153.77 (IP153.77) and 2′,5′-oligoadenylate synthetase 1 (OAS1), in IFN-treated 293T cells revealed that the expression of wild-type ZIKV NS5, but not of NS5 Mut<sup>YRDH1</sup> led to a dose-dependent reduction of ISG54 and OAS-1 expression (Fig. 5c).

Previous studies have shown that ZIKV NS5, in addition to its suppression of hSTAT2, inhibits IFN-β production through targeting the retinoic-acid-inducible gene I (RIG-I) pathway. We thus further investigated the effects of ZIKV NS5 mutations on type I IFN suppression along the RIG-I signaling pathway. Toward this, we performed an IFN-β promoter-driven luciferase assay to determine whether the NS5 mutation also affects the RIG-I-(2CARD)-, TANK-binding kinase 1 (TBK1)-, and interferon regulatory factor-3 (IRF3)-activated IFN-β expression (Fig. 5c). The replication efficiency of VSV, which is impaired in the presence of high levels of IFN, was increased in A549 cells treated with supernatants from cell cultures transfected with wild-type NS5 compared with that in those treated with NS5 Mut<sup>YRDH1</sup> (Fig. 5b), suggesting that the NS5 Mut<sup>YRDH1</sup> mutation impaired NS5-mediated suppression of IFN production. Consistent with these results, quantitative PCR with reverse transcription (RT–qPCR) analysis of two representative type I IFN-stimulated genes, IFN induced protein 153.77 and 2′,5′-oligoadenylate synthetase 1 (OAS1), in IFN-treated 293T cells revealed that the expression of wild-type ZIKV NS5, but not of NS5 Mut<sup>YRDH1</sup> led to a dose-dependent reduction of ISG54 and OAS-1 expression (Fig. 5c).

ZIKV NS5–hSTAT2 interaction is required for efficient viral infection of IFN-competent cells. Finally, we sought to determine the effect of the ZIKV NS5–hSTAT2 interaction on ZIKV infection. Toward this end, we first introduced different NS5 mutations to the cDNA-ZIKV-MR766 construct, a rescue plasmid that has previously been used for generating recombinant MR766 ZIKV 95. Next, we generated both the recombinant wild-type (rWT) virus

---

Table 2 | Cryo-EM data collection, refinement and validation statistics

| Data collection and processing | ZIKV NS5–hSTAT2 (EMD-21618, PDB 6WCZ) |
|---|---|
| **Magnification** | x130,000 |
| **Voltage (kV)** | 300 |
| **Electron exposure (e-/Å<sup>2</sup>)** | 48 |
| **Defocus range (μm)** | 1.0–3.0 |
| **Pixel size (Å)** | 1.07 |
| **Symmetry imposed** | C<sub>1</sub> |
| **Initial particle images (no.)** | 868,048 |
| **Final particle images (no.)** | 118,760 |
| **Map resolution (Å)** | 4.0 |
| **FSC threshold** | 0.143 |
| **Map resolution range (Å)** | 3.5–7.0 |
| **Refinement** | | |
| **Initial model used** | 6UX2 |
| **Model resolution (Å)** | 4.0 |
| **FSC threshold** | 0.143 |
| **Model resolution range (Å)** | 4.0–274 |
| **Map sharpening B factor (Å<sup>2</sup>)** | −167 |
| **Model composition** | | |
| **Non-hydrogen atoms** | 9,893 |
| **Protein residues** | 1,231 |
| **Ions (zinc)** | 2 |
| **B factors (Å<sup>2</sup>)** | | |
| **Protein** | 153.77 |
| **Ions (zinc)** | 106.22 |
| **R.m.s. deviations** | | |
| **Bond lengths (Å)** | 0.01 |
| **Bond angles (°)** | 1.01 |
| **Validation** | | |
| **MolProbity score** | 2.55 |
| **Clashscore** | 13.3 |
| **Poor rotamers (%)** | 2.08 |
| **Ramachandran plot** | | |
| **Favored (%)** | 86.98 |
| **Allowed (%)** | 13.02 |
| **Disallowed (%)** | 0 |
Fig. 3 | Cellular analysis of the ZIKV NS5-hSTAT2 interaction. a–c, Ribbon and surface view showing the NS5 RdRP-hSTAT2 interaction (a), with the details for the CCD- and ND-mediated interactions highlighted in expanded views in b and c, respectively. Hydrogen bonds are shown as dashed lines. d–f, Ribbon and surface view of the NS5 MTase-hSTAT2 interaction (d), with details highlighted in expanded views in e and f. g, h, Co-IP analysis showing the effects of hSTAT2 mutations (g) and NS5 mutations (h) on the NS5-hSTAT2 interaction. Immunoblot analysis of the IP and whole-cell extract (WCE) was performed using antibodies against HA, FLAG and GAPDH. i, Representative IF images of 293T cells transfected with plasmids encoding NS5-HA and/or hSTAT2-FLAG. The transfected cells were fixed for immune staining using antibodies against HA (red) and FLAG (green). Nuclei were visualized by DAPI (blue) counter staining. Scale bars, 20 μm. Uncropped blots for g and h are shown in Supplementary Data 1.
and the mutant viruses through transfecting 293T cells with the complementary DNA-ZIKV-MR766 construct, as described previously\textsuperscript{39}. Interestingly, the rescue plasmids carrying the Y25A (MutY), H855A (MutH), MutRDH or MutYRDH mutation failed to yield recombinant viruses, likely owing to a severe attenuation effect caused by these mutations. Nevertheless, we were able to rescue viruses with wild-type or R327A NS5. Additionally, we rescued a D734A-containing virus, in which an additional mutation, G338E, recurrently emerged after several passages in Vero cells during two independent rescue processes.

Both of those two mutant ZIKV exhibited similar replication kinetics as rWT ZIKV did in IFN-deficient Vero cells\textsuperscript{40} (Fig. 6a), with the exception of the 12h after infection where the mutant titers were slightly higher than those of rWT ZIKV. This discrepancy may have arisen from the fact that the viral titer counting was based on plaque phenotype, or the factors influencing early viral growth. We then performed multicyle growth-curve experiments using IFN-competent A549 cells, which were infected by the different mutant viruses at a multiplicity of infection (MOI) of 1. Nevertheless, compared with rWT ZIKV, both mutant viruses yielded substantially (up to 3 orders of magnitude) reduced virus titers after 48h following infection (Fig. 6b), suggesting an IFN-dependent attenuation effect for the R327A and G338E D734A NS5 mutations. Note that co-IP and IF analyses of 293T cells transfected with ZIKV NS5 and/or hSTAT2 indicated that the G338E D734A mutation affects the NS5-hSTAT2 interaction and cellular localization of ZIKV NS5 in a manner similar to that of the D734A or MutYRDH mutation (Fig. 3i and Extended Data Fig. 10a,b). Likewise, the R327A mutation also impairs the interaction and cytoplasmic colocalization of ZIKV NS5 and hSTAT2, albeit to a lesser extent (Extended Data Fig. 10a,b). Consistently, both mutations compromised the NS5-mediated hSTAT2 degradation in both 293T cells and virus-infected A549 cells (Extended Data Fig. 10c,d). Together, these data establish that the hSTAT2-NS5 interaction is critical for productive ZIKV infection under IFN-competent condition.

**Discussion**

The STAT family of proteins, in particular STAT1 and STAT2, plays critical roles in eliciting IFN responses against viral infection.
Not surprisingly, these proteins are among the first targets of viral attacks. To date, the molecular basis for virus-mediated suppression of STAT function remains unclear, due to a lack of structural information on the complexes formed between STATs and any viral antagonist. The structural, biochemical, cellular and viral-infection analyses of the ZIKV NS5–hSTAT2 and DENV-2 NS5–hSTAT2 complexes presented here reveal the principle underlying the interactions between STAT proteins and viral antagonists. This study not only provides mechanistic insights into the IFN suppression by a viral antagonist, but also sheds light onto the rational design of vaccine or other therapeutic strategies against viral infections.
Flavivirus NS5 proteins have widely evolved into an antagonist for IFN signaling\(^{13–15,41–46}\). For instance, NS5 proteins from ZIKV, DENV and yellow fever virus have been shown to interact with hSTAT2 to promote its degradation\(^{13,14}\) or to prevent its binding to promoter elements of target genes\(^{43}\). How the sequence and conformation of flavivirus NS5 were shaped to underpin its antagonistic activity remains elusive. The structures of ZIKV NS5–hSTAT2 and DENV-2 NS5–hSTAT2 complexes reveal multivalent interactions. The interdomain cleft between the MTase and RdRP domains of the NS5 protein provides a shape complementarity with the CCD of hSTAT2 for specific molecular recognition. This interaction mode is shared between ZIKV NS5 and DENV NS5, suggesting a conserved mechanism for the interactions between hSTAT2 and flavivirus NS5 proteins (Fig. 6c). As the largest and most conserved flavivirus protein, NS5 has been shown to exist in multiple conformations in solution, presumably due to the weak MTase-RdRP domain interaction\(^{24,25,32,33,47,48}\). So far, structural evidence has revealed two alternative conformations of flavivirus NS5, corresponding to two distinct domain interfaces: the structures of free ZIKV NS5, DENV-2 NS5 and JEV NS5 represent an extended fold, with a large interdomain cleft exposed to solvent\(^{24,25,47,48}\). By contrast, the crystal structure of DENV-3 NS5 exhibits a compact fold, with a less accessible MTase–RdRP domain interface, a conformation that is closely related to the NS5-mediated RNA replication\(^{32}\). Given that these two alternative domain interfaces are both conserved in sequence\(^{49}\), it is conceivable that the two conformations of NS5 coexist in solution. The structures of the hSTAT2-bound either DENV-2 NS5 or ZIKV NS5 presented in this study indicated that both proteins adopt the extended conformation for hSTAT2 interaction, suggesting a conformational selection mechanism in their binding to hSTAT2 (Fig. 6c).

Structural and biochemical analyses presented in this study demonstrate that the interaction between ZIKV NS5 and hSTAT2 may lead to multiple functional consequences. Intriguingly, we observed that ZIKV NS5 competes against IRF9 for the same interaction interface on hSTAT2, potentially leading to suppression of formation of the ISGF3 complex. In light of the critical role of the ISGF3 complex in STAT2-mediated IFN response, these data suggest that ZIKV NS5 suppresses hSTAT2 not only...
through promoting its proteasome-mediated degradation, but also through blocking the formation of the ISGF3 complex. Inhibition of the ISGF3 complex not only suppresses antiviral gene expression, but might also affect the nuclear shuffling of hSTAT2 and its proteasome-mediated degradation, therefore constituting a multifaceted regulatory mechanism of hSTAT2 suppression (Fig. 6c). It is worth noting that previous studies have identified multiple mechanisms for nuclear relocation of flavivirus NS5s. For instance, a carboxy-terminal 18-residue fragment of DENV-2 NS5 has been shown to mediate its nuclear localization; such a fragment is not conserved in DENV-1 NS5, leading to cytoplasmic localization of DENV-1 (ref. 50). Given the diversity between different serotypes of DENV, it is worth noting that the mechanism by which the hSTAT2 interaction affects DENV's other than serotype 2 remains to be determined. In addition, a recent study has identified residues K390–R393 of ZIKV NS5 as a nuclear localization sequence, which mediates the association of ZIKV NS5 with importin α to form supramolecular nuclear bodies in cells. In this regard, this study mapped the hSTAT2-interaction sites onto distinct regions of ZIKV NS5 (Figs. 1 and 2) or DENV-2 NS5 (Fig. 4a,b), suggesting that the interaction of NS5 with hSTAT2 would not prevent its binding to importin, thereby implying the existence of a novel mechanism for cytoplasmic retention of ZIKV NS5. Our data also indicate that the interaction between hSTAT2 and ZIKV NS5 potentially impairs the activity of the NS5 protein through reducing its RNA-binding affinity (Extended Data Fig. 6e), suggesting multilayered functional antagonism between hSTAT2 and ZIKV NS5.

A common theme among all members of the STAT family is the pY-dependent dimerization. The crystal structures of homodimeric STAT1, STAT3 and STAT6 reveal that dimerization of STATs is mediated by the mutual SH2-pY association, reinforced by the antiparallel pairing of the tail segment immediately downstream of the pY site. However, how the phosphorylation event triggers the monomer-dimer transition of STATs remains unclear. Surprisingly, the structure of hSTAT2 presented in this study reveals that the unphosphorylated pY-tail segment of hSTAT2 folds back to block the pY-binding site of the SH2 domain, with phosphorylation site Y690 interacting with SH2 through side-chain hydrogen-bonding interactions (Extended Data Fig. 2a). Phosphorylation of hSTAT2 Y690 presumably would lead to impaired tail-SH2 association of hSTAT2, permitting the repositioning of the tail segment for an intermolecular interaction, thereby providing a potential autoinhibitory mechanism in controlling the dimerization of STAT2 or other STATs. Furthermore, our modeling analysis suggests that the STAT1–STAT2 dimer adopts the same architecture as the STAT1 homodimer, and presents a potential DNA-binding surface of the hSTAT2 transcript. Collectively, these data provide a framework for understanding the regulation and structure of the ISGF3 complex.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41594-020-0472-y.

Received: 30 December 2019; Accepted: 25 June 2020;
Published online: 10 August 2020

References
1. Hoffmann, H. H., Schneider, W. M. & Rice, C. M. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 36, 124–138 (2015).
2. Sadler, A. J. & Williams, B. R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559–568 (2008).
3. Chowdhury, F. Z. & Farrar, J. D. STAT2: a shape-shifting anti-viral super STAT. JAKSTAT 2, e23633 (2013).
4. Lim, C. P. & Cao, X. Structure, function, and regulation of STAT proteins. Mol. Biostat. 2, 536–550 (2006).
5. Shuai, K. et al. Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76, 821–828 (1994).
6. Blaszczyk, K. et al. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 29, 71–81 (2016).
7. Fu, X. Y., Kessler, D. S., Veals, S. A., Levy, D. E. & Darnell, J. E. Jr ISGF3, the transcriptional activator induced by interferon α, consists of multiple interacting polypeptide chains. Proc. Natl Acad. Sci. USA 87, 8555–8559 (1990).
8. Plataniitis, E. et al. A molecular switch from STAT2–IRF8 to ISGF3 underlies interferon-induced gene transcription. Nat. Commun. 10, 2921 (2019).
9. Brierley, M. M. & Fish, E. N. Stats: multifaceted regulators of transcription. J. Interferon Cytokine Res. 25, 733–744 (2005).
10. Rasmussen, S. A., Jamieson, D. J., Honein, M. A. & Petersen, L. R. Zika virus and birth defects—reviewing the evidence for causality. N. Engl. J. Med. 374, 1981–1987 (2016).
11. Cao-Lormeau, V. M. et al. Guillain–Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531–1539 (2016).
12. Dubber, D. J. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11, 480–496 (1998).
13. Ashour, J., Laurent-Rolle, M., Shi, P. Y. & Garcia-Sastre, A. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83, 5408–5418 (2009).
14. Grant, A. et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19, 882–890 (2016).
15. Morrison, J. et al. Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling. PLoS Pathog. 9, e1003265 (2013).
16. Davidson, A. D. Chapter 2. New insights into flavivirus nonstructural protein 5. Adv. Virus Res. 74, 41–101 (2009).
17. Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT1-dimer bound to DNA. Cell 93, 827–839 (1998).
18. Mao, X. et al. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell 17, 761–771 (2005).
19. Becker, S., Groner, B. & Müller, C. W. Three-dimensional structure of the T3-j homodimer bound to DNA. Nature 394, 145–151 (1998).
20. Li, J. et al. Structural basis for DNA recognition by STAT6. Proc. Natl Acad. Sci. USA 113, 13015–13020 (2016).
21. Neculai, D. et al. Structure of the unphosphorylated STAT5a dimer. J. Biol. Chem. 280, 40782–40787 (2005).
22. Duan, W. et al. The crystal structure of Zika virus NS5 reveals conserved virus drug targets. EMBO J. 36, 934–933 (2017).
23. Godoy, A. S. et al. Crystal structure of Zika virus NS5 RNA-dependent RNA polymerase. Nat. Commun. 8, 14764 (2017).
24. Wang, B. et al. The structure of Zika virus NS5 reveals a conserved domain conformation. Nat. Commun. 8, 14763 (2017).
25. Zhao, B. et al. Structure and function of the Zika virus full-length NS5 protein. Nat. Commun. 8, 14762 (2017).
26. Shuai, K., Stark, G. R., Kerr, J. I. M. & Darnell, J. E. Jr A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science 261, 1744–1746 (1993).
27. Improta, T. et al. Transcription factor ISGF3 formation requires phosphorylated Stat91 protein, but Stat113 protein is phosphorylated independently of Stat91 protein. Proc. Natl Acad. Sci. USA 91, 4776–4780 (1994).
28. Uchil, P. D., Kumar, A. V. & Satchidanandam, V. Nuclear localization of flavivirus RNA synthesis in infected cells. J. Virol. 80, 5451–5464 (2006).
29. Martinez-Moczygemba, M., Gutch, M. J., French, D. L. & Reich, N. C. Distinct STAT structure promotes interaction of STAT2 with the p48 subunit of the interferon-α-stimulated transcription factor ISGF3. J. Biol. Chem. 272, 20070–20076 (1997).
30. Nengachari, S. et al. Structural basis of STAT2 recognition by IRF8 reveals molecular insights into ISGF3 function. Proc. Natl Acad. Sci. USA 115, E601–E609 (2018).
31. El Sahili, A. et al. NS5 from dengue virus serotype 2 can adopt a novel inter-domain interface essential for protein flexibility and virus replication. PLoS Pathog. 11, e1004682 (2015).
32. Bussetta, C. & Choi, K. H. Dengue virus nonstructural protein 5 adopts multiple conformations in solution. Biochemistry 51, 5291–5303 (2012).
33. Chaudhary, V. et al. Selective activation of type II interferon signaling by Zika virus NS5 protein. J. Virol. 91, e0163–17 (2017).
35. Kumar, A. et al. Zika virus inhibits type-I interferon production and downstream signaling. EMBO Rep. 17, 1766–1775 (2016).
36. Speer, S. D. et al. ISG15 deficiency and increased viral resistance in humans but not mice. Nat. Commun. 7, 11496 (2016).
37. Xia, H. et al. An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat. Commun. 9, 414 (2018).
38. Hertzog, J. et al. Infection with a Brazilian isolate of Zika virus generates RIG-I stimulatory RNA and the viral NS5 protein blocks type I IFN induction and signaling. Eur. J. Immunol. 48, 1120–1136 (2018).
39. Schwarz, M. C. et al. Rescue of the 1947 Zika virus prototype strain with a cytomegalovirus promoter-driven cDNA clone. Msphere 1, e00246–16 (2016).
40. Emeny, J. M. & Morgan, M. J. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43, 247–252 (1979).
41. Best, S. M. et al. Inhibition of interferon-stimulated JAK–STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 79, 12828–12839 (2005).
42. Laurent-Rolle, M. et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK–STAT signaling. J. Virol. 84, 3503–3515 (2010).
43. Laurent-Rolle, M. et al. The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon. Cell Host Microbe 16, 314–327 (2014).
44. Lin, R. J., Chang, B. L., Yu, H. P., Liao, C. L. & Lin, Y. L. Blocking of interferon-induced Jak–Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. J. Virol. 80, 5908–5918 (2006).
45. Lubick, K. J. et al. Flavivirus antagonism of type I interferon signaling reveals proolidase as a regulator of IFNAR1 surface expression. Cell Host Microbe 18, 61–74 (2015).
46. Mazzon, M., Jones, M., Davidson, A., Chain, B. & Jacobs, M. Dengue virus NS5 inhibits interferon-α signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 200, 1261–1270 (2009).
47. Lu, G. & Gong, P. Crystal structure of the full-length Japanese encephalitis virus NS5 reveals a conserved methyltransferase-polymerase interface. PLoS Pathog. 9, e1003549 (2013).
48. Upadhyay, A. K. et al. Crystal structure of full-length Zika virus NS5 protein reveals a conformation similar to Japanese encephalitis virus NS5. Acta Crystallogr. F Struct. Biol. Commun. 73, 116–122 (2017).
49. Wang, B., Thurmond, S., Hai, R. & Song, J. Structure and function of Zika virus NS5 protein: perspectives for drug design. Cell. Mol. Life Sci. 75, 1723–1736 (2018).
50. Tay, M. Y. et al. The C-terminal 18 amino acid region of dengue virus NS5 regulates its subcellular localization and contains a conserved arginine residue essential for infectious virus production. PLoS Pathog. 12, e1005886 (2016).
51. Ng, I. H. W. et al. Zika virus NS5 forms supramolecular nuclear bodies that sequester importin-α and modulate the host immune and pro-inflammatory response in neuronal cells. ACS Infect. Dis. 5, 932–948 (2019).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2020
Methods

Protein expression and purification. For structural studies, the cDNA sequences encoding full-length ZIKV NS5, its MTAse (residues 1–273) and RdRP (residues 273–903) domains, full-length DENV-2 NS5, an N-terminal fragment of hSTAT2 (residues 73–371), and full-length human IRF9 were each cloned into a modified pRSFDuet-1 vector (Novagen), preceded by a polyhistidine (His6)-SUMO tag and ubiquitin like protease 1 (UPL1) cleavage site. For in vitro pull-down assays, the cDNA sequence encoding full-length hSTAT2 was cloned into the pGEX6P-1 vector (GE Healthcare). Expression and purification of the His6-SUMO-tagged ZIKV NS5, full length or fragments, and hSTAT21–y179 were accomplished in an iterative process involving protocol with slight modifications. In short, the NS5 or hSTAT21–y179 fusion proteins were expressed in E.coli BL21 DE3 (RIL) cell strains (Agilent Technologies) and purified sequentially using a Ni2+-NTA column and a butyl Sepharose column (GE Healthcare). The His6-SUMO tag was subsequently removed through UPL1-mediated cleavage, followed by size-exclusion chromatography on a Superdex 200 16/600 column (GE Healthcare) pre-equilibrated with buffer containing 25 mM Tris-HCl (pH 7.5), 500 mM NaCl, 5 mM DTT and 5% glycerol. His6-SUMO-tagged IRF9 was expressed and purified similarly as ZIKV NS5 and hSTAT2, except that additional ion-exchange chromatography on a heparin column was introduced between Ni2+-NTA chromatography and size-exclusion chromatography. Protein solutions of RdRP and hSTAT21–y179, respectively, were concentrated to 20 mg ml–1 and 30 mg ml–1 for storage. For GST pull-down assays, the GST-tagged full-length hSTAT2 protein was first purified using a glutathione Sepharose Fast Flow 4 column, followed by ion-exchange chromatography on a Heparin column (GE Healthcare) and size-exclusion chromatography on a Superdex 200 16/600 column (GE Healthcare), using the buffer as described above. Expression and purification of DENV-2 NS5, and ZIKV NS5 and hSTAT221–y222 mutants followed the same approach as that for wild-type proteins, except that purification of DENV-2 NS5 did not require the butyl Sepharose step.

Crystalization and X-ray structure determination. To assemble the NS5 RdRP–hSTAT2 complex, equimolar ZIKV RdRP and hSTAT21–y179 were mixed to achieve a final protein concentration of ~6 mg ml–1. The crystallization condition was initially identified via sparse matrix screening kits (Qiagen), and further optimized through hanging-drop vapor diffusion method by mixing 1 μl of the ZIKV RdRP–hSTAT21–y179 complex with 1 μl of precipitant solution (0.2 M ammonium sulfate, 11% PEG 8000 and 0.1 M Tris-HCl, pH 8.5). Crystals were equilibrated in a cryo-protectant comprised of precipitant solution supplemented with additional 30% glycerol, and were subsequently flash-frozen in liquid nitrogen. The X-ray diffraction data for the ZIKV RdRP–hSTAT2 complex were collected on the BL 5.0.1 beamline at the Advanced Light Source, Lawrence Berkeley National Laboratory. The diffraction data were processed using the HKL2000 program. The complex structure was solved by the molecular replacement method using Phaser with the structures of free ZIKV NS5 (PDB ID: 5TMH) and human STAT1 (PDB ID: 1YV1) as search models. The structure was further refined by iterative model building and refinement with Coot and Phenix, respectively. The statistics of data collection and structure determination are summarized in Table 1.

Cryo-EM data acquisition. The protein samples of hSTAT21–y222 and ZIKV NS5 were mixed in a 1:1 ratio, followed by size-exclusion chromatography on a Superdex 200 10/300 column (GE Healthcare) pre-equilibrated with buffer containing 25 mM Tris-HCl (pH 7.5), 175 mM NaCl, 5 mM DTT. The peak was collected and subjected to negative-stain electron microscopy for sample optimization. For cryo-EM sample preparation, an aliquot of 2.5 μl of the above optimized ZIKV NS5–hSTAT21–y222 sample at a concentration of approximately 0.5 mg ml–1 was applied to a Quantifoil holey carbon grid (1.2/1.3, 300 mesh), that was glow discharged for 25 s with a PELCO Easy Glow system. The grid was blotted and plunged-frozen in liquid ethane with a Vitrobot IV (Thermo Fisher) at 4 °C under 100% humidity. The frozen grids were stored in liquid nitrogen before use. For cryo-EM image acquisition, the cryo-EM grids were loaded into a FEI Titan Krios electron microscope equipped with Gatan Quantum imaging filter (GIF) and a post-GIF K2 Summit direct electron detector. Movies were recorded as dose-fracionated frames in super-resolution mode with a nominal magnification of ×130,000, corresponding to a calibrated pixel size of 0.15 Å per pixel for side-chain conformations were optimized. Ramachandran and secondary-structure restraints were used during the refinement. Our final atomic model consisted of the full-length NS5 and residues 140–509 of hSTAT2 with good model geometry, as summarized in Table 2.

Negative-stain data acquisition and structure determination. The protein samples of hSTAT21–y222 and DENV-2 NS5 were mixed in a 1:1 ratio, and purified in the same manner as that for the hSTAT21–y222–ZIKV NS5 complex. An aliquot of 3 μl of the complex sample was then applied to the carbon-coated grid and incubated for 4 min. After removal of the excess sample solution, the grid was stained with 1% (wt/vol) uranyl formate. Negative-stain EM micrographs were acquired manually and with a TiETZ F415MP 16-megapixel CCD camera at 100 kV (for magnification at an accelerating voltage of 200 kV). The micrographs were saved by 2× binning to yield a pixel size of 4.4 Å. For negative-stain EM data processing, 138,246 particles were extracted from 300 micrographs using RELION. These particles were subjected to a reference-free 2D classification by requesting 100 classes. Based on the 2D class averages results, we selected 116,778 particles, which were subjected to a 3D classification by requesting 3 classes. The initial reference used for this 3D classification step was generated by cryoSPARC from the same particles. On the basis of the 3D-classification results, 35,062 particles in one class were subjected to 3D autorefinement, yielding a map at about 17.1 Å resolution (Fig. 4a and Extended Data Fig. 9e,f). The crystal structures of the MTAse domain and RdRP domains of DENV-2 NS5 (from this study) were respectively fitted into the EM map by using the ‘fit in map’ routine in Chimera.

Cryo-EM data processing. All but the first and last frames in each movie were motion-corrected with a 5 × 5 subframe to generate 2 motion-corrected micrographs (with and without dose-weighting), which were both binned 2×2 to yield a pixel size of 1.07 Å with MotionCor2 (ref. 57). These micrographs without dose-weighting were used for particle extraction and 3D reconstruction, as detailed below.

We selected 1,762 micrographs by discarding those either with underfocus values greater than 3.0 μm, or containing crystalline ice. A total of 1,088,157 particles were extracted from these selected micrographs using RELION. These particles were subjected to a reference-free 2D classification by requesting 200 classes. On the basis of the presence of structures in the two-dimensional class averages, we selected 868,048 particles (Supplementary Fig. 2), which were subjected to a three-dimensional (3D) classification in RELION with C1 symmetry. The initial reference used for this 3D classification step was generated by cryoSPARC from the same particles. The 3D classification was used to sort particles into 3 classes with 5 pixels and 3.8° as the translation and rotation search radius, respectively. These particles were used for the classification of secondary structures features (Supplementary Fig. 2). The particles in this 'good' class were then subjected to another round of 3D classification by requesting three classes, which further yielded a ‘new' good class with improved structural features. The 118,760 particles in this new ‘good' class were subjected to 3D autorefinement and post-process, yielding a map at about 17 Å resolution (Supplementary Data Fig. 3). The data-processing workflow is detailed in Supplementary Fig. 2.

The global resolution reported above is based on the ‘gold standard’ refinement procedures and the 0.143 Fourier shell correlation (FSC) criterion. Local resolution evaluation (Extended Data Fig. 3) was performed with Resmap.

Atomic model building based on the cryo-EM map. Atomic model building was accomplished in an iterative process involving Coot, Chimera and Phenix. Briefly, the above crystal structure of ZIKV RdRP–hSTAT2 was fitted into the cryo-EM map as an initial model by using the ‘fit in map’ routine in Chimera. This fit revealed the extra density corresponding to MTAse domain and the absence of density corresponding to RdRP, suggesting high flexibility of ND in solution (initially, the ND is partially disordered). The cryo-EM densities for SH2 and partial LD were of insufficient quality for model building. The crystal structure of the MTAse domain (PDB: 20M65) fits perfectly into the cryo-EM density and was combined with our crystal structure of NS5 RdRP–hSTAT2, to create an initial atomic model for NS5–hSTAT2, which was refined by real-space refinement in Phenix. We then manually adjusted side chains and linker loops to match the cryo-EM density map with Coot. This process of real space refinement and manual adjustment steps was repeated iteratively until the peptide backbone and side-chain conformations were optimized. Ramachandran and secondary-structure restraints were used during the refinement. Our final atomic model consisted of the full-length NS5 and residues 140–509 of hSTAT2 with good model geometry, as summarized in Table 2.
Electrophoretic mobility shift assay. ZIKV NS5–RNA complex formation was assayed with an in vitro transcribed, cap-1 yeast mRNA (YLR164W, 749 nt), by agarose gel electrophoretic mobility shift. NS5 and STAT2 stocks were first diluted to 1 μM in TBE (HEPES-Tris 34 mM Tris, 57 mM HEPES, adjusted to pH 7.5 with glacial acetic acid; 0.1 mM EDTA, 300 mM NaCl, 0.05% (vol/vol) Tween 20, 25% (vol/vol) glycerol, 2 mM DTT, 0.2 mg ml−1 BSA). The mRNA was diluted to 522 ng μl−1 (～2 μM) in water, heated to 65°C for 5 min in a dry block, then snap-cooled in ice. Final samples (7.5 μl) contained RNA (52 ng μl−1), NS5 (110 nM), and STAT2 (90 nM), which were incubated using pPEI with 0.25 μg each of pCAGGS encoding hSTAT1- or hSTAT2-FLAG and ZIKV/DENV-2 NS5-HA, or their mutants. At about 48 hpt, cells were fixed and permeabilized with methanol for 20 min at −20°C, and then blocked with 3% BSA/0.2% Tween 20/PBS at 30°C for 1 h. The cells were incubated with mAb anti-HA and rabbit anti-FLAG primary antibodies (catalog no. 14795S, Cell Signaling) for 1 h at 30°C, followed by two 5-min washes with PBS+0.2% Tween (50 mL), then washed with PBS+0.2%, followed by goat anti-mouse and Alexa Fluor 488-conjugated anti-rabbit secondary antibodies to add the cells for 1 h at 30°C. After two additional washes with PBS, the coverslips were mounted onto slides with Vectashield (Vector Laboratories) containing DAPI. Images were captured using a Leica SP5 confocal microscope. Confoical laser scanning was performed using a Zeiss LSM 880 Meta (Carl Zeiss Microimaging) fitted with a Plan Achromatic ×63/1.4 or ×40/1.4 oil objective lens. Images were collected at 16 bits and a resolution of 1,024 × 1,024 pixels. A total of 100 cells per condition were counted and analyzed by microscopy. Image processing and analysis were carried out using Fiji/ImageJ software.

RT-qPCR. To quantify ISG44 mRNA levels in the presence of NS5 or NS5 mutants, 5 × 104 293T cells were transfected with pCAGGS encoding HA-tagged NS5 and NS5 MutTHDM. At 30 hpt, the transfected cells were primed with 2 μg polycycl (EC) transfection. Then, 18 h later, serial 1:2 dilutions of the supernatants from cultures transfected with the NS5 variants were used to treat A549 cells. At 24 h after infection, cells were not treated with VSV–GFP (gift from D. Boganovic) an MOI of 1. Infected cells were visualized 24 h post-infection for GFP expression by the Nikon Eclipse ti-2000 U fluorescence microscope.

Statistics and reproducibility. Data are presented as the mean ± s.d. of at least three independent experiments. For analysis of the RT-qPCR results, two-tailed Shapiro-Wilk's test was used with a confidence interval of 95% (the degrees of freedom is 4). For the analysis of the growth curves, the two-way analysis of variance test was used to evaluate significant differences (for comparison of viruses in Vero cells, degrees of freedom is 2 and F value is 1.849; for comparison of viruses in A549 cells, degrees of freedom is 2 and F value is 55.84). For both analyses, a P value of less than 0.05 was considered significant. All biochemical and cellular assays were performed three or more times with similar results, unless indicated otherwise.
**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**
Coordinates and structure factors for the ZIKV RdRP–hSTAT21–713 complexes have been deposited in the Protein Data Bank with accession code PDB 6UX2. Cryo-EM density map and atomic coordinates of the NS5–hSTAT2 complex have been deposited in the EMDB and PDB under the accession codes EMD-21618 and PDB 6WCZ, respectively. Uncropped images and source data for the graphs are available in Supplementary Data 1 and 2, respectively.

**References**
52. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. *Method Enzymol.* 276, 307–326 (1997).
53. McCoy, A. J. et al. Phaser crystallographic software. *J. Appl. Crystallogr.* 40, 658–674 (2007).
54. Emsley, P. & Cowtan, K. *Coot*: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* 60, 2126–2132 (2004).
55. Adams, P. D. et al. *PHENIX*: building new software for automated crystallographic structure determination. *Acta Crystallogr. D Biol. Crystallogr.* 58, 1948–1954 (2002).
56. Sulkoway, C. et al. Automated molecular microscopy: the new Leginon system. *J. Struct. Biol.* 151, 41–60 (2005).
57. Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* 14, 331–332 (2017).
58. Zhang, K. Gctf: real-time CTF determination and correction. *J. Struct. Biol.* 193, 1–12 (2016).
59. Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J. Struct. Biol.* 180, 519–530 (2012).
60. Scheres, S. H. A Bayesian view on cryo-EM structure determination. *J. Mol. Biol.* 415, 406–418 (2012).
61. Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat. Methods* 14, 290–296 (2017).
62. Vilas, J. L. et al. MonoRes: automatic and accurate estimation of local resolution for electron microscopy maps. *Structure* 26, 337–344 (2018).
63. Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* 25, 1605–1612 (2004).

**Acknowledgements**
This work was supported by a UC Cancer Research Coordinating Committee Faculty Seed Grant (CRR-20-634140) to J.S., and the NIH (1R35GM119721 to J.S., 1R21AI147057 to J.S. and R.H., R01GM071940 to Z.H.Z., R21 AI133649 to M.J.E. and R00GM111858 to S.E.O.). This work is also partly funded by the Trans fund of the State of California (AB2664) to I.S. and R.H., and by DHIPC (Dengue Human Immunology Project Consortium) and a NIAID funded program (U19AI118610) to A.G.-S. M.J.E. holds Investigator in Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund. K.Z. was partially supported by a fellowship from the China Scholarship Council. We acknowledge the assistance of D. Carter for microscopy imaging. Microscopy and/or image analysis was also performed at the Microscopy CoRE at the Icahn School of Medicine at Mount Sinai. We thank G. Tan for assisting with statistical analysis on the growth-curve data. We also acknowledge the use of instruments at the Electron Imaging Center for Nanomachines supported by UCLA and by instrumentation grants from NIH (1S10RR23657, 1S10OD018111 and U24GM116792) and NSF (DBI-1338135 and DMR-1548924). We would like to thank staff members at the Advanced Light Source, Lawrence Berkeley National Laboratory, for access to X-ray beamlines. The Advanced Light Source is supported by the director, office of science, office of basic energy sciences, of the US Department of Energy under contract no. DE-AC02-05CH11231. We thank S. Ding and D. Bogunovic for providing the DENV cDNA clone and VSV–GFP virus, respectively. We also thank Z. Hu for insightful discussions.

**Author contributions**
B.W., S.T., K.Z., M.T.S.-A., J.F., J.L., L.G., W.R., Y.C., H.H., S.E.O., R.H. and J.S. performed experiments and data analysis. E.C.V. and M.J.E. provided technical support. R.H. and J.S. conceived the project, A.G.-S., Z.H.Z., R.H. and J.S. supervised the study. B.W., S.T., K.Z., Z.H.Z., R.H. and J.S. wrote the manuscript and all authors approved the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41594-020-0472-y.

Correspondence and requests for materials should be addressed to Z.H.Z., R.H. or J.S.

Peer review information Inês Chen was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | Structural analysis of the RdRP domain of ZIKV NS5 in complex with hSTAT2_{1-713}. a, The structure of the NS5 RdRP-hSTAT2_{1-713} complex, with hSTAT2_{1-713} shown as electrostatic surface and RdRP shown as ribbon diagram. The two zinc clusters of NS5 RdRP are shown in expanded views, surrounded with Fo-Fc omit map (orange) contoured at 2.0 σ level. b, Two opposite views of the structure of the NS5 RdRP-hSTAT2_{1-713} complex, with hSTAT2_{1-713} shown as ribbon diagram and RdRP shown as electrostatic surface. The RNA entrance and exit tunnels of NS5 RdRP are marked with dashed circles (yellow). The disordered linkers of hSTAT2_{1-713} are depicted as dashed lines. N- and C-termini are indicated by letter ‘N’ and ‘C’. c, d, Fo-Fc omit maps (violet) of selected residues for intermolecular interactions at the RdRP-CCD (c) and RdRP-ND (d) interfaces, contoured at 2.0 σ level. The color schemes for the RdRP and hSTAT2 are the same as that in Fig. 1.
Extended Data Fig. 2 | Structural comparison of hSTAT2 and hSTAT1. a, Ribbon representations of the CF of hSTAT2 (cyan) in association with its pY-tail segment (grey). The intramolecular interaction between the SH2 domain and the unphosphorylated pY-tail segment of hSTAT2 is highlighted in the expanded view. The hydrogen bonds are depicted as dashed lines. b, Ribbon representation of homodimeric hSTAT1 in complex with DNA, with the intermolecular interaction between the hSTAT1 SH2 domain (light pink) and the phosphorylated pY-tail segment from the other monomer (yellow) of the hSTAT1 homodimer shown in the expanded view. c, Sequence alignment of the pY-tail segments of human STAT proteins. Identical and similar residues are marked in red and blue, respectively. The target tyrosine is shaded in yellow. d, Structural model of the ZIKV NS5–hSTAT2–hSTAT1–DNA complex, with the surface electrostatic view of the hSTAT2 DBD shown in the expanded view.
Extended Data Fig. 3 | Cryo-EM analysis of the ZIKV NS5–hSTAT2 complex. 

**a**, A representative cryo-EM micrograph with select particles circled. 

**b**, 2D class averages used to generate the model. 

**c**, Local resolution evaluation of the reconstructed map by Resmap. 

**d**, **e**, Angular distribution (d) and global resolution evaluation based on ‘gold-standard’ Fourier shell correction (FSC) (e), both generated by RELION.
Extended Data Fig. 4 | Details of the cryo-EM densities overlaid with their atomic models (ribbon) of the domains in ZIKV NS5–hSTAT2 complex.  

a, Ribbon representations of the atomic model of NS5–hSTAT2, with NS5 (left) and hSTAT2 (right) overlaid with their respective density maps. b, c, Details for the MTase–CCD interaction, with densities of interacting residues shown as mesh. d, Details for the RdRP–CCD interaction, with densities of interacting residues shown as mesh. e–j, MTase, NE and Fingers, Thumb, and Palm domains in NS5.
Extended Data Fig. 5 | Biochemical analysis of the interaction between ZIKV NS5 and hSTAT2. a, Co-IP assay of 293T cells transfected with plasmids encoding C-terminally HA-tagged NS5 (NS5-HA) and FLAG-tagged hSTAT2 (hSTAT2-FLAG) or hSTAT1 (hSTAT1-FLAG). Immunoblot analysis of the whole cell extract (WCE) was used as input. IP was performed using antibodies against HA, FLAG and GAPDH. *antibody heavy chain. b, GST pull-down assay of the MTase and RdRP domains of ZIKV NS5 using GST-tagged full-length hSTAT2. c, Size-exclusion chromatography analysis of the interaction between hSTAT2-713 and ZIKV NS5. d, SDS-PAGE analysis of the elution fractions in (c). Uncropped gel images for a, b, d are shown in Supplementary Data 1.
Extended Data Fig. 6 | Structural analysis of the ZIKV NS5–hSTAT2 interaction. **a,** Superposition of the crystal structure of NS5 RdRP–hSTAT21-713 (grey) and the cryo-EM structure of full-length NS5–hSTAT21-713 (cyan). While the cryo-EM structure contains the MTase domain, there is no change in the relative orientations of different domains between the two structures. **b,** Structural superposition of free (PDB 5TMH) and hSTAT2-bound ZIKV NS5. The conformational transition of the MTase domain of ZIKV NS5 from free state to the hSTAT2-bound state is indicated by arrows. For clarity, all the hSTAT2 domains, except for the CCD, were removed. **c,** Surface view of the MTase domain of ZIKV NS5 bound to hSTAT2 CCD (green ribbon). The four helices of the CCD are sequentially numbered from ‘1’ to ‘4’. The potential RNA binding site is indicated by dashed circle. **d,** Surface of the DENV-3 MTase bound to viral cap-0 RNA (PDB 5DTO). **e,** hSTAT2 inhibition of ZIKV NS5–RNA binding assayed by electrophoretic mobility shift. Addition of NS5 to a cap-1 (mGpppG230w) yeast mRNA (YLR164W, 749 nt) resulted in a shift of the RNA band. Further addition of STAT2 resulted in release of RNA from the NS5–RNA complex, with concomitant accumulation of free RNA. Uncropped gel image for **e** is shown in Supplementary Data 1.
Extended Data Fig. 7 | Mutational analysis of the interaction between ZIKV NS5 and hSTAT2. **a**, IP analysis of endogenous hSTAT2 in 293T cells transfected with WT or mut^{YRDH} NS5. Immunoblot was performed using antibodies against hSTAT2, HA, and GAPDH. **b**, In vitro pull-down assay of ZIKV NS5 mutations using GST-hSTAT2 as bait. wt: wild type. The experiment was repeated twice with consistent results. **c**, Quantification of nuclear localization of NS5, WT or mutants as shown in Fig. 3i. Data are mean ± s.d. (n = 3 biologically independent samples). Uncropped gel or blot images for **a**, **b** and source data for graphs in **c** are shown in Supplementary Data 1 and 2, respectively.
Extended Data Fig. 8 | ZIKV NS5 competes against IRF9 for hSTAT2 binding. a, Ribbon and surface view of the ZIKV NS5-binding sites (orange) of hSTAT2 CCD. b, Ribbon and surface view of the ZIKV NS5-binding sites (blue) of mouse STAT2 CCD. c, d, ITC binding curves of hSTAT2 over ZIKV NS5 (c) and IRF9 (d). The ITC binding assays were performed twice for the hSTAT2-NS5 interaction with similar results, and once for the hSTAT2-IRF9 interaction. e, Co-IP assay of HA-tagged ZIKV NS5 (NS5-HA), FLAG-tagged hSTAT2 (hSTAT2-FLAG) or hSTAT1 (hSTAT1-FLAG) and Myc-tagged IRF9 (IRF9-Myc). f, In vitro pull-down assay of ZIKV NS5 using GST-hSTAT2 in the presence of various amount of IRF9. g, IP assay of IRF9-Myc with hSTAT2-FLAG, wild type or mutant. The experiment in (g) was repeated once with similar results. Uncropped gel or blot images for e-g are shown in Supplementary Data 1.
Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | Sequence and structural analyses of the DENV NS5–hSTAT2 interaction. a–c, Sequence conservation analysis of the ZIKV NS5–hSTAT2 interaction using the ConSurf server (https://consurf.tau.ac.il/). The sequence conservation of hSTAT2 and ZIKV NS5 residues are colored coded and mapped onto the crystal structure of ZIKV RdRP–hSTAT2 (a) and cryo-EM structure of ZIKV NS5–hSTAT2 (b, c). d, Sequence alignment of the NS5 proteins from members of the *Flaviviridae* family, with the identical residues colored in red and the hSTAT2-binding sites of ZIKV NS5 marked by green asterisks. e, Representative negative-stain EM image of DENV NS5–hSTAT2, Bar: 40 nm. f, Characteristic 2D class averages with CTF correction. g, Structural overlay of DENV-3 NS5 and hSTAT2-bound ZIKV NS5. The potential steric clash between the ‘closed’ conformation of DENV-3 NS5 (PDB 4V0Q) and hSTAT2 is marked by a red circle.
Extended Data Fig. 10 | Cellular analysis of the R327A (MutR) and G338E/D734A (MutGD) mutations of ZIKV NS5 on the hSTAT2 interaction and degradation. 

**a**, Co-IP analysis showing the effects of MutR and MutGD in comparison with D734A (MutD) and MutYRDH on the NS5–hSTAT2 interaction. Immunoblot analysis of the IP and whole cell extract (WCE) was performed using antibodies against HA, FLAG and GAPDH. 

**b**, IF analysis of 293T cells transfected with plasmids encoding NS5-HA, wild type or mutant, and hSTAT2-FLAG. The transfected cells were fixed for immune staining using antibodies against HA (red) and FLAG (green). Nuclei were visualized by DAPI (blue) counter staining. 

**c**, Immunoblot analysis of 293T cells transfected with indicated plasmids encoding wild-type or mutant NS5-HAs using antibodies against HA, hSTAT2, and GAPDH, incubated with or without proteasome inhibitor MG132. 

**d**, Western-blot analysis of virus-infected A549 cells using antibodies against hSTAT2 and GAPDH. Uncropped blots for **a**, **c**, **d** are shown in Supplementary Data 1.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a | Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Software and code

Policy information about availability of computer code

Data collection
X-ray diffraction data were collected from synchrotron beamline BL5-01 at Advanced Light Source (ALS), Lawrence Berkeley National Laboratory Laboratory. The cryoEM data were collected from an FEI Titan Krios electron microscope at the Electron Imaging Center for Nanomachines supported by UCLA

Data analysis
For X-ray structural study, the HKL2000, PHENIX, Coot and Pymol softwares were used for data processing and analysis. For cryoEM and negative-stain data, the eMTfit, Gautomatch, RELION, cryoSPARC, Resmap, Coot, Chimera and Phenix softwares were used for data processing and analysis. For confocal IF microscopy, Fiji/ImageJ software was used for data analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Coordinates and structure factors for the 2IKV RdRP – hSTAT2[1-713] complexes have been deposited in the Protein Data Bank with accession code 6UX2. CryoEM density map and atomic coordinates of the NSS–hSTAT2 complex have been deposited to the EMDB and PDB under the accession numbers EMD-21638 and 6WCZ, respectively. Source data are available with the paper online, or Supplementary Data 1 and 2.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

- Sample size: Biochemical assays were completed using wild type or mutants of ZIKV N55 or hSTAT2. Cellular and virological assays were completed using wild type or mutant ZIKV N55, DENV-2 NS5 or hSTAT2 plants. The sample size is sufficient to delineate the mutational effects of NS5s and hSTAT2.
- Data exclusions: No data exclusion.
- Replication: Data are presented as the mean ± SD of at least two independent experiments. For cellular and virological assays, at least 3 biological replicates were used and stated in figure legends. Statistical analysis was performed with Student’s t test for comparing two sets of data with assumed normal distribution. A p value of less than 0.05 was considered to be significant.
- Randomization: The assays performed in this study require a rational approach for activity comparison. Therefore, randomization is not applicable to our experimental set up.
- Blinding: Blinding is not applicable to any biochemical or cellular assay performed in this study.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|---------------------------------|---------|
| n/a                             | n/a     |
| ☑ Antibodies                    | ☑ ChiP-seq |
| ☑ Eukaryotic cell lines         | ☑ Flow cytometry |
| ☑ Palaeontology                 | ☑ MRI-based neuroimaging |
| ☑ Animals and other organisms   |         |
| ☑ Human research participants   |         |
| ☑ Clinical data                 |         |

Antibodies

Antibodies used: Antibodies used for immunoblotting include anti-Flag (Sigma, F1804), anti-HA (Thermo-Fisher, Catalog #26183), anti-GAPDH (VWR, Catalog#13087-384) and goat anti-mouse IgG (H+L) HRP-linked secondary antibody (Thermo-Fisher, Catalog#31165).

Validation: They were validated by the manufacturers.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s): The source of each eukaryotic cell line was described in the section of ’Cell lines and viruses’.

Authentication: Authentication of cell line identity, including that of parental and derived lines, was ensured by using the genetic signature profiling analysis and observed for cell morphology routinely.

Mycoplasma contamination: All cells were tested mycoplasma negative using the PlasmoTest™ kit (InvivoGen) following the standard protocol.

Commonly misidentified lines (See CCLAC register): N/A